Serendipity and science aside, AZ-Oxford Covid-19 vaccine analysis raises many questions

The shortened dosing pattern of the Covid-19 vaccine candidate from the AstraZeneca-Oxford University combine has ended up raising several questions from the scientific community. An interim analysis shared just days ago on the AZ-Oxford vaccine revealed that they had given a shortened half-a-dose first, followed by a second full dose to trial participants. And this achieved greater efficacy, than two full doses.

While an AZ representative called it “serendipity”, it has triggered off queries on whether the protocol has since been changed on the clinical trial and whether it would require changes at the production level as well.

At the global media interaction on the interim analysis, the rationale for the shortened dosing was not explained, except to say that it was seen to work better and more work needed to be done. But in subsequent interactions, company officials reportedly clarified that a manufacturing error had resulted in the changed

Read More

Logmore Launches First Logistics Monitor Designed for COVID-19 Vaccine Delivery

HELSINKI–(BUSINESS WIRE)–November 25, 2020–

Supply chain analytics solution provider Logmore has announced the launch of its latest product. Logmore Dry Ice, a high-spec version of Logmore’s original data recorder, has been adapted for cold and sub-zero conditions. The solution is designed for sensitive shipments, such as the COVID-19 vaccine the moment it becomes available.

This press release features multimedia. View the full release here:

COVID 19 Logistics Monitor by Logmore (Photo: Logmore)

COVID 19 Logistics Monitor by Logmore (Photo: Logmore)

Since its founding in 2017, Logmore has disrupted logistics monitoring with its use of loggers that sync with the cloud using dynamic QR codes, allowing anyone with a smartphone to update secure systems with the latest conditions and locations of shipments.

Logmore Dry Ice redefines monitoring of cold chain shipments from standard fridge temperatures (2-8°C) all the way down to deep freeze levels of -100°C. This makes it ideal for transporting the COVID-19 vaccines, which require deep

Read More

China Vaccine Maker Applies for Public Use of Covid Shot

(Bloomberg) — A leading Chinese vaccine developer has applied for authorization to bring its Covid-19 shot to the market, seeking to get a jump on Western rivals as the race for a working inoculation against the virus enters the final stretch.

a group of items on a table: Technicians processing Covid-19 coronavirus tests at a laboratory in Tianjin, China.

© Source: AFP/Getty Images
Technicians processing Covid-19 coronavirus tests at a laboratory in Tianjin, China.

China National Biotec Group Co. has submitted an application to Chinese regulators, reported state media Xinhua Finance on Wednesday, citing parent company Sinopharm’s vice general manager Shi Shengyi. The application likely includes interim data from the company’s Phase III human testing conducted in the Middle East and South America.


Load Error

Stocks related to Sinopharm Group, including its Hong Kong unit, surged on Wednesday after the news.

A CNBG spokeswoman said she had no further information when contacted by Bloomberg. Calls to Sinopharm Group went unanswered.

With the application, CNBG will likely become the

Read More

Pfizer vaccine refutes Trump’s nationalism, science attacks

Pfizer’s announcement that its COVID-19 vaccine is 95% effective has created significant optimism — except in the Trump camp, where adverse reactions of cynicism have emerged. His acolytes believe the press release was timed to prevent an injection of good news that might have secured reelection.

It is true that Pfizer’s CEO wanted to distance his scientists from the overt politics that would have come with taking Operation Warp Speed money. The company didn’t take funding but entered into an agreement to supply the United States with vaccine once the Food and Drug Administration approved. Trump’s adult children believe this pact was a result of their father’s deal-making prowess — but such supply agreements are quite common.

Whether the release was sat on and prevented a second term for Trump is likely never to be known. Regardless, Americans should feel relief because nothing about this vaccine is to his credit.

Read More

Russia says data on Sputnik Covid vaccine shows 95% efficacy

Russia has said that its coronavirus vaccine had more than 95% efficacy according to new preliminary data, giving it a success rate comparable to vaccines being developed by Pfizer and Moderna.The country also said claimed it had greater efficacy than the Oxford/AstraZeneca vaccine because of Russia’s proprietary technology, which it offered to share with British scientists.

a hand holding a bottle: Photograph: Natalia Kolesnikova/AFP/Getty Images

© Provided by The Guardian
Photograph: Natalia Kolesnikova/AFP/Getty Images

a close up of a hand holding a bottle: Kirill Dmitriev, who has been tasked with selling the vaccine abroad, said on Tuesday that a dose would cost about $10 on international markets about half the cost of the Pfizer vaccine.

© Photograph: Natalia Kolesnikova/AFP/Getty Images
Kirill Dmitriev, who has been tasked with selling the vaccine abroad, said on Tuesday that a dose would cost about $10 on international markets about half the cost of the Pfizer vaccine.

Read More

Stocks edge higher on Wall Street on latest vaccine hopes

Stocks edged higher in afternoon trading Monday after investors received several pieces of encouraging news on COVID-19 vaccines and treatments, tempering concerns over rising virus cases and business restrictions

The benchmark S&P 500 index rose 0.3%, led by banks, industrial companies and other businesses that have been beaten down by the virus.

The latest vaccine developments are helping to raise hopes that some normalcy will eventually be restored to everyday life and the economy. It is also tempering lingering concerns about new government controls as the virus spikes in

Read More

Vaccine mRNA research from Moderna, Pfizer vs COVID huge for science


Pfizer and Moderna have both announced promising results in the phase 3 trials of their COVID-19 vaccines. Here’s how they differ.


The success of two COVID-19 candidate vaccines marks a turning point in the long history of vaccines and could lead to major advances against a variety of diseases.

Vaccines developed by Pfizer/BioNTech and Moderna are more than 95% effective against COVID-19, trials show. Both depend on a technology never before used in a commercial vaccine that could upend the way future ones are made.

This new messenger RNA technology, as well another method that depends on viruses to deliver vaccines, are transforming the field, said Brendan Wren, a professor of vaccinology at the London School of Hygiene and Tropical Medicine.

“It could be quite a new era for vaccines and vaccinology,” he said. “We seemed to move ahead in this one year 10 years.”

These technologies had

Read More

Facebook plans to woo Biden with vaccine, climate change features: FT

  • Facebook is building a strategy to help get on President-elect Joe Biden’s good side, company sources told the Financial Times.
  • Facebook is reportedly planning to crack down harder on COVID-19 misinformation, and is considering adding an information banner to its site encouraging users to get vaccinated.
  • Facebook is also reportedly looking at ways to encourage users to engage with content about the Paris Climate Agreement, which Biden has pledged to rejoin. The US left the agreement in November.
  • Facebook plans to make Nick Clegg its main point of contact with Washington, the FT reported. Clegg was deputy prime minister in Britain during Biden’s term as vice-president.
  • Visit Business Insider’s homepage for more stories.

Facebook is gearing up to woo President-elect Joe Biden by promoting vaccine and climate change information, according to a report from the Financial Times.

Citing anonymous company “insiders,” the FT reports Facebook is planning to crack down

Read More

Fauci says herd immunity possible if enough Americans take vaccine

Dr. Anthony Fauci, the nation’s top infectious diseases expert, said Sunday the U.S. could reach herd immunity against the coronavirus “reasonably quickly” next year if enough Americans get vaccinated.

Anthony S. Fauci wearing a suit and tie: screen-shot-2020-11-22-at-10-37-44-am.png

© CBS News

Appearing on “Face the Nation,” Fauci said “help is on the way” in the form of the vaccine, but Americans need to exercise caution as the holidays approach and take steps to mitigate the spread of the virus through the winter, saying the country is in a “very, very difficult situation” as cases continue to rise. Vaccines will be available “relatively soon” if Americans can “hang in there,” Fauci said. 

Vaccines produced by Pfizer and Moderna have been shown to be highly effective, but Fauci said herd immunity — the threshold at which enough people have been vaccinated or infected by the virus to curtail its spread — can’t be achieved if only 40% or 50% of

Read More

Vaccine December; Thanksgiving travel; normalcy May


A coronavirus vaccine might not be widely available until several months into 2021.


Plans call for 20 million Americans to be vaccinated in December and another 30 million each month, with some semblance of normalcy returning to the country as soon as May, Operation Warp Speed chief science adviser Dr. Moncef Slaoui said Sunday.

Pfizer submitted an emergency use application for its vaccine to the Food and Drug Administration on Friday. The FDA takes up the application Dec. 10. Slaoui, who made the rounds of the morning news shows Sunday, told NBC’s Meet the Press that vaccines will be shipped to every state within 24 hours of FDA approval of that application.

“On the 11th or on the 12 of December hopefully the first people will be immunized across the United States, across all states,” Slaoui told CNN’s “State of the Union.”

Health care workers and highly

Read More